| Literature DB >> 25379381 |
Y I Ishida1, M Takikawa2, T Suzuki2, M Nagahama1, Y Ogasawara2.
Abstract
Peroxiredoxin 2 (Prx2) is the third most abundant protein in red blood cells (RBCs). In this study, we have succeeded in implementing the rapid and simultaneous detection of the hyperoxidized (Prx2-SO2/3) and reduced (Prx2-SH) forms of Prx2 in human RBCs using reverse phase high-performance liquid chromatography. The detection of a peak corresponding to Prx2-SO2/3 was clearly observed following treatment of tert-butyl hydroperoxide (t-BHP), but not H2O2, and was found to be dose-dependent. The identity of the peak was confirmed as Prx2 by immunoblotting and mass spectrometry analysis. Our results suggest that t-BHP hyperoxidizes cysteine residues in Prx2 more readily than H2O2, and that accumulation of hyperoxidized Prx2 might reflect disruption of redox homeostasis in RBCs.Entities:
Keywords: Biomarker; DTPA, diethylenetriaminepentaacetic acid; DTT, dithiothreitol; HPLC, high-performance liquid chromatography; Hyperoxidation; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; Oxidative stress; PBS, phosphate-buffered saline; PMF, peptide mass fingerprinting; Peroxiredoxin 2; RBC, red blood cell; ROS, reactive oxygen species; Red blood cell; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; TFA, trifluoroacetic acid; TOF, time-of-flight; t-BHP, tert-butyl hydroperoxide; tert-Butyl hydroperoxide
Year: 2014 PMID: 25379381 PMCID: PMC4215121 DOI: 10.1016/j.fob.2014.10.003
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Fig. 1Chromatograms of human RBC lysate as analyzed by reverse phase chromatography and Western blot analysis. Reverse phase HPLC was performed using an YMC-pack PROTEIN-RP column (4.6 × 250 mm) as described in Section 2. The separated proteins were collected in 1.0 ml fractions and concentrated using a centrifugation concentrator system (Sakuma, Tokyo, Japan) for further analysis. After concentration, all fractions (3–50 min) were subjected to Western blot analysis with anti-Prx2 antibody after 12% SDS–PAGE and transfer to a PVDF membrane. RBC lysates were prepared after treatment with 500 μM H2O2 (B), t-BHP (C) or without peroxide (A). A typical result from the other three samples providing similar results is presented.
Fig. 2Dose dependent alterations in peak areas obtained by reverse phase chromatography. HPLC was performed using a reverse phase column for proteins, as described in Section 2. RBC lysates were prepared after treatment with 0–500 μM t-BHP. Peak b and Peak c are indicated on the chromatogram as shown in Fig. 1B.
Fig. 3Protein identification by MS analysis. RBCs were treated with or without 500 μM t-BHP and proteins contained in fractions corresponding to peaks a and c in Fig. 1 were prepared. The proteins were separated using 12% SDS–PAGE and detected by silver staining. Protein bands No. 1 and No. 2 were excised and subjected to in-gel digestion and PMF using MALDI–TOF–TOF-MS. Proteins derived from bands No. 1 and No. 2 were identified as human Prx2 (Accession; P32119).
Fig. 4Oxidative status of Prx2 in human RBCs analyzed by 2D-PAGE and Western blot analysis. Prx2 from freshly obtained RBCs that were untreated (A) or treated (B) with 500 μM t-BHP was subjected to 2D-PAGE as described in Section 2. The separated and transferred proteins were detected by Western blotting with anti-Prx2 (upper image) or anti-Prx-SO2/3 (lower image). A typical result from two other samples exhibiting similar responses is presented.
Fig. 5Oxidative status of Prx2 in human RBCs following t-BHP treatment. An RBC lysate was prepared after treatment with 500 μM t-BHP. After concentration, each fraction was subjected to Western blot analysis with anti-Prx2 antibody (A; upper image) and reprobed with anti-Prx-SO2/3 antibody (B; lower image). Peaks b and c are indicated on the chromatogram. A typical result from two other samples exhibiting similar responses is presented.